Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-No U.S. rate rise until 2024?

Fri, 30th Apr 2021 10:07

* Europe's STOXX 600 up 0.1%

* Basic materials index worst performer, down 1%

* Barclays tumbles after cautious guidance

* Healthcare stock index leads gains up 0.8%

April 30 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

NO U.S. RATE RISE UNTIL 2024? (0905 GMT)

A Fed tapering might be dangerous for equities, but we
should also ask ourselves if investors have already priced that
in.

UBS analysts have a pretty clear idea on the matter. They
expect “discussions on bond purchase tapering (by the Fed) to
surface in the second half of the year.”

But they “believe markets have largely priced in this
expectation.” In addition, they “do not expect any rate hike
until 2024.”

This would mean that equities will benefit from the
ultra-loose policy by the U.S. government, without worrying
about yields for a reasonable length of time.

But there are still reasons to expect more market turbulence
“as investors fret over rising inflation and the uneven global
progress in combating the pandemic,” UBS analysts say.

Bottom line, equities can rise further, but better to be
exposed to the “cyclical part of the market such as financials,
energy and value stocks.”

The chart shows the 10-year U.S. bond yields and the U.S.
dollar forward inflation-linked swap.

(Stefano Rebaudo)

*****

EARNINGS PROP UP STOXX, BUT BANKS UNDER PRESSURE (0745 GMT)

European stocks opened slightly higher as a batch of solid
company results boosted risk sentiment and offset worries about
rising bond yields.

The STOXX 600 index is up 0.2% with autos,
construction and materials stocks leading gains. Banks
are on the negative side, down 0.7% after yesterday’s
rise.

Barclays shares are down 5.5% after results.

Shares in AstraZeneca are rising 2.7% after the
company reports Q1 profit and sales ahead of expectations and
forecast higher sales in Q2.

Swiss Re stocks are up 4% after the company swang
to Q1 net profit, which was better than analysts expectations.

Investors will focus on today’s eurozone inflation figures
which might add more fuel to the fire of worries about rising
yields. Some analysts see upside risks, while most see a modest
decline in core numbers.

Eyes also on the U.S. core PCE Price Index with analysts
expecting a sizable jump.

(Stefano Rebaudo)

*****

EUROPE MAY OFFER STEER FOR WEEKEND CHEER (0658 GMT)

It's Europe's turn to confirm an improving global outlook,
a day after strong U.S. data and upbeat earnings lifted the S&P
500 to a record high close.

So far, so good: BNP Paribas, the euro zone's biggest listed
lender, posted a better-than-expected first-quarter profit while
Q1 profit at British bank Barclays more than doubled.

Next up is GDP data. Ahead of a euro-wide number released
later this morning, France revealed its economy grew a
stronger-than-expected 0.4% in Q1, having shrunk 1.4% in the
final quarter of 2020.

The euro zone economy is forecast to have shrunk 2% in the
first quarter year-on-year, versus a 4.9% fall in the final
quarter of last year.

A flash inflation estimate is also due; economists forecast
a 1.6% rise in the headline number in April versus a 1.3%
increase in March.

These figures may seem underwhelming compared to the United
States, which grew at a 6.4% annualized rate last quarter. Yet
sentiment appears to have turned a corner thanks to a pick-up in
the COVID vaccination rollout and signs economic activity has
held up relatively well in the face of ongoing restrictions.

That view perhaps is why Germany's 10-year Bund yield is
ending April almost 10 basis points higher -- even
as the U.S. equivalent is down 10 bps.

The recovery expectations, alongside upbeat earnings have
underpinned stocks, although Asian shares slipped on Friday and
European stock futures were a touch lower.

Copper, the other key growth barometer, also slipped after a
blistering rally to $10,000 a tonne, though it is on track for
the 12th monthly gain in the past 13 months.

Finally, the U.S. dollar skidded toward a fourth straight
weekly decline against a basket of peers, undermined by the
Federal Reserve's message of ultra-low rates for longer.

Key developments that should provide more direction to
markets on Friday:

- Earnings calendar: Exxon Mobil, Chevron, AbbVie, Charter
Communications, AstraZeneca.

-Nestle has bought the brands of vitamin and supplements
maker The Bountiful Company for $5.75 billion

-Darktrace lists in London but valuation well below reported
target

- U.S. March personal spending and income numbers due out.

- Credit Suisse board member Gottschling to exit after
Greensill, Archegos losses

- China official manufacturing PMI fell to 51.1 in April.

-British house prices posted the biggest single-month
increase since 2004

- Retailer Amazon posted record Q1 profits.

(Dhara Ranasinghe)

*****

EUROPE SUBDUED ON YIELDS RISE, CHINA WORRIES (0528 GMT)

European stock futures are slightly lower with no clear
trend emerging yet as a rise in yields is expected to put
pressure on some equity sectors while a mixed picture on Asian
markets dampens risk sentiment.

China stocks lost ground overnight after weak data on
concerns about a monetary policy tightening coupled with
Sino-U.S. tensions. U.S. President Joe Biden took aim at China
in his first speech to Congress, pledging to maintain a strong
U.S. military presence Indo-Pacific.

Biden's new spending plan and the dovish stance by the Fed
continue to support risk-appetite along with U.S. data released
yesterday, which showed American economic growth accelerated in
the first quarter.

(Stefano Rebaudo)

*****

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.